24   PHARMACEUTICAL EXECUTIVE     GROWTH     BOTTOM                          from the     By Patrick Clinton and Jerry Cac...
MAy 2012 www.pharmexec.com                         25Top 20 Global Products   Product                                     ...
26 26                 PHARMACEUTICAL EXECUTIVE      PHARMACEUTICAL EXECUTIVE                                              ...
28 28                 PHARMACEUTICAL EXECUTIVE      PHARMACEUTICAL EXECUTIVE                                              ...
30 30                 PHARMACEUTICAL EXECUTIVE      PHARMACEUTICAL EXECUTIVE                                              ...
32 32                 PHARMACEUTICAL EXECUTIVE      PHARMACEUTICAL EXECUTIVE                                              ...
34                     PHARMACEUTICAL EXECUTIVE                                                                           ...
Upcoming SlideShare
Loading in …5
×

Top 50 Pharmaceutical Companies 2011, Pharma Exec Report

9,835 views

Published on

0 Comments
2 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
9,835
On SlideShare
0
From Embeds
0
Number of Embeds
19
Actions
Shares
0
Downloads
223
Comments
0
Likes
2
Embeds 0
No embeds

No notes for slide

Top 50 Pharmaceutical Companies 2011, Pharma Exec Report

  1. 1. 24 PHARMACEUTICAL EXECUTIVE GROWTH BOTTOM from the By Patrick Clinton and Jerry Cacciotti of Oliver Wyman Up MORE CONSOLIDATION DIDN’T BOOST SALES AT THE TOP, BUT A HANDFUL OF NIMBLE NEWCOMERS POSTED IMPRESSIVE GROWTH ON THE OTHER END OF THE CURVE had sales of at least $2 billion. This year, the smallest, Aspen, had sales of $1.66 billion. The drop is even steeper when you look at revenue as a percentage of the total revenues of the whole Pharm Exec 50. Last year’s smallest company accounted for 0.4 per- cent of the total revenue of all 50 companies in the ranking. This year, the equivalent fi gure was 0.2 percent—only half as big a percentage. By way of comparison, in 2004, the fi rst year when all 50 com- panies had sales of more than $1 billion, the smallest company accounted for 0.3 percent of the revenue of the 50. New additions include a reincarnated Valeant (44), formed when Biovail—Canada’s largest publicly held pharma, a specialist in CNS drugs and delivery—pur- chased the American firm for $3.3 billion, adopting T his year’s Pharm Exec 50 shows an industry whose its name and putting Valeant CEO Michael Pearson in growth has slowed to a crawl in the face of patent ex- charge of the combined operation. Endo Pharmaceuti- pirations, aggressive payers, and a tough environment cals (45) is currently in the process of “reinventing” itself for approvals. The 50 this year sold $610 billion in human with a new business model and name (Endo Health Solu- prescription pharmaceuticals, up just 2.8 percent from last tions); the company grew its branded and prescription year’s $593 billion. The top 10 grew even more slowly—by pharmaceutical business by 38 percent in 2011. Grifols, just 2.6 percent—and accounted for 59 percent of the 50’s the Spanish manufacturer of plasma fractionation prod- total sales, just like last year. ucts (47), grew revenues by more than 80 percent, partly In a year in which investors have looked with increas- as a result of the acquisition of US-based Talecris. And ing disfavor on large R&D budgets, R&D spending grew finally, Aspen Pharmacare, the 50’s first African com- by just 4.5 percent, from $101 billion to $105. Among the pany, grew its revenues by 29 percent last year, and its top 10, R&D was almost fl at, growing by just 1.6 percent. CAGR since 1998 is 46 percent. The company has been Four companies dropped off the 50 because of mergers: expanding its footprint, most recently by the acquisition Genzyme (last year’s number 29), now a part of Sanofi of Australia’s Sigma. Aventis; Alcon (previously 39), which was acquired by While some of the data this year may be a little de- Novartis; Cephalon (previously 40), which is now a part pressing (incidentally, the anti-depression class of drugs of Teva; and Nycomed (previously 48), bought by Takeda. jumped to number one in the US, surpassing lipid regu- The consolidation that knocked these companies off lators), the hint of diversity and new ideas creeping up the list had another effect: The companies at the bottom from the bottom of the list is a cause—albeit a small-cap of the list are smaller. Every company in the 50 last year one—for optimism. *Special thanks to the IMS Institute for Healthcare Informatics and IMS Health for supplemental data Getty Images / Jed Share
  2. 2. MAy 2012 www.pharmexec.com 25Top 20 Global Products Product 2011 % Change 1 Lipitor 12.5 –3.3 2 Plavix 9.3 3.7 3 Seretide 8.7 0.04 4 Crestor 8.0 14.4 Source: IMS Health, MIDAS, December 2011 5 Nexium 7.9 –6.2 6 Seroquel 7.6 9.5 7 Humira 7.3 17.8 8 Enbrel 6.8 6.7 9 Remicade 6.8 8.4 10 Abilify 6.3 14.3 11 Singulair 6.1 10.8 12 Zyprexa 5.7 –3.113 Mabthera 5.7 8.6 14 Lantus 5.5 15.2 15 Avastin 5.4 –7.516 Herceptin 4.8 7.917 Cymbalta 4.7 19.2 18 Spiriva 4.7 13.6 19 Neulasta 4.2 9.4 20 Glivec 4.1 6.5 Figures are in US$ billions. Growth rates in US$ are not recommended due to extreme fluctuations in the value of the dollar The figures above include prescription and certain over the counter data and represent manufacturer prices Sales cover direct and indirect pharmaceutical channel wholesaler and manufacturersTop 20 Global Therapeutic Classes Class 2011 2010 % Change 1 Oncologics 62.2 23.2 5.5 2 Respiratory Agents Source: IMS Health, MIDAS, December 2011 39.4 21.0 7.3 3 Antidiabetics 39.2 20.1 11.4 4 Lipid Regulators 38.7 19.6 3.7 5 Antipsychotics 28.4 18.2 9.4 6 Angiotensin II Antagonists 27.4 12.0 –0.7 7 Anti-Ulcerants 26.9 11.0 –6.4 8 Autoimmune Agents 24.4 10.3 14.1 9 Antidepressants 20.4 10.1 –1.5 10 HIV Antivirals 17.4 8.3 9.5 11 Platelet Aggr. Inhibitors 16.4 7.9 4.1 12 Anti-Epileptics 14.1 7.8 10.1 13 Vitamins & Minerals 13.9 7.6 6.1 13.4 7.1 13.0 14 Vaccines 0.7 15 Narcotic Analgesics 12.3 6.3 12.0 5.9 0.6 16 Cephalosporins 11.8 5.2 3.817 Multiple Non-Narcotic Analgesics 11.7 5.1 15.8 18 Hospital Solutions 11.4 4.5 7.9 19 Anti-Rheumatics, Non-Steroidal 10.8 3.7 5.4 Figures are in US$ billions. Growth rates in US$ are not recommended due to extreme fluctuations in the value of the dollar The figures above include prescription and certain over the counter data and represent manufacturer prices Sales cover direct and indirect pharmaceutical channel wholesaler and manufacturersChannel Distribution by US Dispensed Prescriptions and US Sales Miscellaneous HMO $1 Retail Channels $2.7 Retail Channels 3,695 Home Health Care $2.8 $227.3 Independent Federal Facilities Chain Stores $4.2 Source: IIMS National Prescription Audit™ 483 Long-Term Care $15.2 $112.6 $38.4 Non-Federal Hospitals 740 260 Food Stores $38.4 2, 2 12 Institutional Channels 5.1 $5 1. 5 329 $38.4 92.6 $2 Clinics Mail Service Mail Service Food Stores Chain Stores Institutional Channels IndependentAt left, prescriptions in millions. At right, sales in US$ billionsReport reflects Prescription-bound products including Insulins (and excludes other products such as OTC)IMS routinely updates its market audits, which can and does result in changes to previously reported market size and growth rates.Updated February 23, 2012
  3. 3. 26 26 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE MAy 2012 www.pharmexec.com Top 25 Corporations by US Prescriptions Corporation 2011 2010 % Change 1 Teva 558.3 645.7 -13.54 2 Mylan 366.3 380.7 -3.78 3 Novartis 289.7 303.8 -4.64 4 Watson 264.1 248.4 6.32 5 Pfizer 220.2 251.8 -12.55 6 Endo Pharm 176.1 152.2 15.7 7 Lupin laboratories 156.1 133.8 16.67 8 Amneal Pharm Source: IMS Health, MIDAS, December 2011 113.8 98.3 15.77 9 Boehringer Ingelheim 88.9 71.2 24.86 10 Merck & co 88.1 100.5 -12.34 11 Astrazeneca 82.3 87.1 -5.51 12 Covidien 77.2 80.1 -3.62 13 Dr Reddys Lab 74.7 63.7 17.27 14 Actavis 72.5 7 0.7 2.55 15 Zydus Cadila 71.8 53 35.47 16 Daiichi Sankyo 68.5 63.4 8.05 17 GlaxosmithKline 67.6 76.5 -11.63 18 Abbott 59.9 63.9 -6.26 19 Hikma Pharma 54.1 45.6 18.64 20 Lilly 50.6 49.2 1.63 21 Aurobindo 46.6 39.6 17.67 22 Forest 43.5 44.2 -1.58 23 Taro Pharma 40.9 39.5 3.54 24 Perrigo 40.6 33 23.03 25 Par Pharm 40.4 43.2 -6.48 TOTAL US SCRIP MARKET: 2011: 4.02 2010: 3.99 0.78% Figures in millions of prescriptions Report reflects Prescription-bound products including Insulins (and excludes other products such as OTC) IMS routinely updates its market audits, which can and does result in changes to previously reported market size and growth rates.Updated February 23, 2012 2012 Company 2011 Rx Sales 2011 R&D spend 2011 Top-Selling Drugs Rank HQ [website] (USD billions) (USD millions) [USD billions] Lipitor [9.6] Pfizer 1 New York [pfizer.com] $57.7 $9,112 Lyrica [3.7] Enbrel [3.7] Diovan/Co-Diovan [5.7] Novartis 2 Basel, Switzerland [novartis.com] $54.0 $9,100 Gleevec/Glivec [4.7] Lucentis [2.1] Singulair [5.5] Merck 3 Whitehouse Sation, NJ [merck.com] $41.3 $8,467 Januvia [3.3] Remicade [2.7] Lantus [5.0] Sanofi 4 Paris, France [sanofi.com] $37.0 $6,007 Lovenox [2.7] Plavix [2.6] MabThera/Rituxan [6.4] Roche 5 Basel, Switzerland [roche.com] $34.9 $7,862 Avastin [5.6] Herceptin [5.6] Seretide/Advair [7.8] GlaxoSmithKline 6 Brentford, England [gsk.com] $34.4 $5,822 Fixotide/Flovent [1.3] Advodart [1.2] Crestor [6.6] AstraZeneca 7 London, England [astrazeneca.com] $33.6 $5,033 Seroquel [5.8] Nexium [4.4] Remicade [5.5] Johnson & Johnson 8 New Brunswick, New Jersey [jnj.com] $24.4 $5,138 Procrit/Eprex [1.6] Risperdal [1.6] Humira [7.9] Abbott 9 Abbott Park, Illinois [abbott.com] $22.4 $4,129 Trilipix/TriCor [1.4] Kaletra [1.2] Zyprexa [4.6] Eli Lilly 10 Indianapolis, Indiana [lilly.com] $21.9 $5,020 Cymbalta [4.2] Alimta [2.5] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. That includes generics, vaccines, and blood frac- tionation products. As far as possible we have excluded OTC products, hospital supplies such as IV fluids, contract manufacturing, and royalty revenue. Whenever possible, we have taken figures from companies’ annual reports and SEO filings. As needed (and especially in the case of privately held companies), we have supplemented these documents with figures from IMS and EvaluatePharma, press coverage, and other sources. All figures represent the fiscal year that ended in 2011. For most American and European companies, that means the year ending December 31, 2011. For many Japanese companies, we used the fiscal year ending March 31, 2011. Foreign currencies were converted using the average midpoint interbank rate for the month following the end of the fiscal year. In a handful of cases we have had to use estimates. These are noted with an asterisk.
  4. 4. 28 28 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE MAy 2012 www.pharmexec.com Top 25 Corporations by US Sales Corporations 2011 2010 % Change 1 Pfizer 25.1 27.2 -7.72 2 AstraZeneca 19.9 19.5 2.05 3 Merck & Co. 19.3 18.6 3.76 4 Novartis 19.2 18 6.67 Source: IMS Health, MIDAS, December 2011 5 Teva 15.1 15.9 -5.03 6 Lilly 14.9 14.3 4.20 7 Roche 14.5 13.8 5.08 8 GlaxoSmithKline 14.2 15.2 -6.58 9 Amgen 13.1 12.7 3.15 10 Johnson & Johnson 12.1 12.9 -6.20 11 Sanofi 11.8 12.2 -3.28 12 Abbott 11.5 10.9 5.50 13 Bristol-Myers Squibb 10.9 9.8 11.22 14 Boehringer Ingelheim 7 6.4 9.38 15 Takeda 6.6 6.7 1.49 16 Mylan 5.6 4.8 16.67 17 Gilead Sciences 5.5 4.7 17.02 18 Novo Nordisk 5.3 4.5 17.78 19 Otsuka 5.2 4.6 13.04 20 Forest Laboratories 5.2 4.7 10.64 TOTAL US SCRIP MARKET: 2011: $319.9 2010: $308.6 3.67% Figures in US$ billions. Report reflects Prescription-bound products including Insulins (and excludes other products such as OTC) IMS routinely updates its market audits, which can and does result in changes to previously reported market size and growth rates.Updated February 23, 2012 2012 Company 2011 Rx Sales 2011 R&D spend 2011 Top-Selling Drugs Rank HQ [website] (USD billions) (USD millions) [USD billions] 11 Bristol-Myers Squibb New York, New York [bms.com] $21.2 $3,800 Plavix [7.1] 12 Teva Petach Tikva, Israel [tevapharm.com] $16.7 $1,080 Copaxone [3.6] 13 Amgen Thousand Oaks, California [amgen.com] $15.3 $3,167 Neulasta/Neupogen [5.2] 14 Takeda Osaka, Japan [takeda.com] $15.2 $3,466 Actos/Glustin [4.7] 15 Boehringer Ingelheim [boehringer-ingelheim.com] $13.8 N/A Spiriva [4.4] 16 Bayer Leverkusen, Germany [bayer.com] $12.8 $1,979 Betaferon/Betaseron [1.4] 17 Daiichi Sankyo Tokyo, Japan [daiichisankyo.com] $11.6 $2,332 Olmesartan [2.9] 18 Novo Nordisk Bagsvaerd, Denmark [novonordisk.com] $11.5 $1,662 NovoLog/NovoRapid [2.2] 19 Astellas Tokyo, Japan [astellas.com] $11.4 $2,607 Lipitor [1.2] 20 Gilead Sciences Foster City, California [gilead.com] $8.1 $1,229 Atripla [3.2] 21 Otsuka Tokyo, Japan [otsuka.com] $7.4 $1,974 Abilify [4.4] 22 Merck KGaA Darmstadt, Germany [merckgroup.com] $7.2 $1,577 Rebif [2.2] Baxter International 23 Deerfield, Illinois [baxter.com] $6.1 $946 Advate [1.9] Mylan 24 Canonsburg, Pennsylvania [mylan.com] $5.5 $294 Generics [N/A] Servier 25 Neuilly-sur-Seine, France [servier.com] $5.0 $1,255 Coversyl [1.6] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded
  5. 5. 30 30 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE MAy 2012 www.pharmexec.com Top 25 US Pharma Products by Prescriptions Product 2011 2010 % Change 1 Hydrocodone/Acetaminophen 136 131.2 3.66 2 Simvastatin 96.6 94.1 2.66 3 Lisinopril 88.6 87.4 1.37 4 Levothyroxine Sodium 74.1 70.5 5.11 5 Amlodipine Besylate 62.1 57.2 8.57 6 Omeprazole (Rx) Source: IMS Health, MIDAS, December 2011 59.3 53.4 11.05 7 Azithromycin 55.3 52.6 5.13 8 Amoxicillin 53.8 52.3 2.87 9 Metformin Hcl 48.4 46.9 3.2 10 Hydrochlorothiazide 48.1 47.8 1.26 11 Alprazolam 47.8 46.3 3.14 12 Furosemide 42.1 43.4 -2.99 13 Lipitor ® 40.8 45.3 -9.93 14 Zolpidem Tartrate 39.4 38 3.68 15 Metoprolol Tartrate 37.8 38.9 -2.83 16 Citalopram Hbr 37.7 32.1 17.45 17 Sertraline Hcl 37.2 35.7 4.2 18 Metoprolol Succinate 34.5 33 4.55 19 Prednisone 33.7 28.7 17.42 20 Atenolol 33.3 36.3 -8.26 21 Gabapentin 33.2 29.3 13.31 22 Tramadol Hcl 32.9 26.8 22.76 23 Oxycodone/Acetaminophen 32.8 31.9 2.82 24 Ibuprofen (Rx) 32.6 31.1 4.82 25 Warfarin Sodium 30.9 32 -3.44 TOTAL US SCRIP MARKET: 2011: 4.02 2010: 3.99 0.78% Figures in millions of prescriptions. Report reflects Prescription-bound products including Insulins (and excludes other products such as OTC) IMS routinely updates its market audits, which can and does result in changes to previously reported market size and growth rates.Updated February 23, 2012 2012 Company 2011 Rx Sales 2011 R&D spend 2011 Top-Selling Drugs Rank HQ [website] (USD billions) (USD millions) [USD billions] Mitsubishi Tanabe 26 Osaka, Japan [mt-pharma.co.jp] $4.7 $788 Remicade [0.7] Celgene 27 Summit, New Jersey [celgene.com] $4.7 $1,600 Revlimid [3.2] CSL 28 Melbourne, Australia [csl.com.au] $4.5 $349 Privigen [n/a] Allergan 29 Irvine, California [allergan.com] $4.4 $902 Botox [1.6] Forest 30 New York, New York [frx.com] $4.2 $715 Lexapro [2.3] Dainippon Sumitomo 31 Osaka, Japan [ds-pharma.com] $4.0 $817 Lunesta [0.6] Shire 32 Dublin, Ireland [shire.com] $4.0 $770 Vyvanse [0.8] Menarini 33 Florence, Italy [menarini.com] $3.9 n/a n/a [n/a] Biogen Idec 34 Weston, Massachusetts [biogenidec.com] $3.8 $1,219 Avonex [2.7] Eisai 35 Tokyo, Japan [eisai.com] $3.7 $1,740 Aricept [3.5] UCB 36 Brussels, Belgium [ucb.com] $3.7 $1,004 Keppra [1.2] Watson 37 Parsippany, New Jersey [watson.com] $3.7 $295 Generic atovastatin [0.1] Purdue 38 Stamford, Connecticut [purduepharma.com] $2.9 N/A OxyContin [2.6] Lundbeck 39 Copenhagen, Denmark [lundbeck.com] $2.7 $620 Cipralex [1.0] Warner Chilcott 40 Dublin, Ireland [wcrx.com] $2.7 $107 Actonel [0.8] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded
  6. 6. 32 32 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE MAy 2012 www.pharmexec.com Top 25 US Pharma Products by Sales Product 2011 2010 % Change 1 Lipitor® 7.7 7.3 5.48 2 Plavix® 6.8 6.1 11.48 3 Nexium® 6.2 6.3 -1.59 4 Abilify® 5.2 4.6 13.04 5 Advair Diskus® 4.6 4.7 -2.13 6 Seroquel® 4.6 4.4 4.55 7 Singulair® Source: IMS Health, MIDAS, December 2011 4.6 4.1 12.19 8 Crestor® 4.4 3.8 15.79 9 Cymbalta® 3.7 3.2 15.63 10 Humira® 3.5 2.9 20.69 11 Enbrel® 3.5 3.3 6.06 12 Remicade® 3.5 3.3 6.06 13 Actos® 3.4 3.5 -2.86 14 Neulasta® 3.3 3 10 15 Rituxan® 3 2.8 7.14 16 Zyprexa® 3 3 0 17 Copaxone® 3 2.3 30.43 18 Lexapro® 2.9 2.8 3.57 19 Oxycontin® 2.9 3.1 -6.45 20 Epogen® 2.8 3.3 -15.15 21 Avastin® 2.7 3.1 -12.9 22 Atripla® 2.6 2.2 18.18 23 Spiriva Handihaler® 2.4 2 20 24 Januvia® 2.1 1.7 23.53 25 Lantus® 2 2 TOTAL US SCRIP MARKET: 2011: $319.9 2010: $308.6 3.66% Figures in US$ billions Report reflects Prescription-bound products including Insulins (and excludes other products such as OTC) IMS routinely updates its market audits, which can and does result in changes to previously reported market size and growth rates.Updated February 23, 2012 Patent expiries Major Patent Expiries in 2012 Sales in 2011 (in billions) Major Patent Expiries in 2012, Ex-US: Plavix / Sanofi-BMS $6.8 Japan: Seroquel Seroquel / AstraZeneca $4.6 UK: Seroquel, Singulair Singulair / Merck $4.6 France: Singulair Actos / Takeda $3.4 Germany: Seroquel Lexapro / Forest $2.9 2012 Company 2011 Rx Sales 2011 R&D spend 2011 Top-Selling Drugs Rank HQ [website] (USD billions) (USD millions) [USD billions] Kyowa Hakko Kirin 41 Tokyo, Japan [kyowa-kirin-pharma.com] $2.7 $543 Nesp/Espo [0.8] Shionogi 42 Osaka, Japan [shionogi.com] $2.6 $611 Crestor [0.3] Hospira 43 Lake Forest, Illinois [hospira.com] $2.6 $358 generic injectables [n/a] Valeant Pharmaceuticals 44 Mississauga, Ontario [valeant.com] $2.4 $65 Welbutrin [219.2] Endo Pharmaceuticals 45 Chadds Ford, Pennsylvania [endo.com] $2.2 $182 Lidoderm [0.8] Actavis 46 Zug, Switzerland [actavis.com] $2.0 n/a Generics [n/a] Grifols 47 Barcelona, Spain [grifols.com] $1.9 $98 Plasma fractionation products [n/a] Actelion 48 Allschwil, Switzerland [actelion.com] $1.8 $486 Tracleer [1.6] Galderma 49 Lausanne, Switzerland [galderma.com] $1.8 $363 Restylane [0.1] Aspen 50 Durban, South Africa [aspenpharma.com] $1.7 $1.3 N/A [n/a] Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded
  7. 7. 34 PHARMACEUTICAL EXECUTIVE MAy 2012 www.pharmexec.com The Top 10 Year In Review 1. Pfizer faced a brutal year of pat- the acquisition of pediatric specialist Topaz Pharmaceuticals and Universal Caprelsa, the first approved therapy for nonoperable advanced medullary thyroid ent expirations in 2011, including not just US exclusivity loss for its leading Medicare, a consumer health company cancer, an orphan condition. Meanwhile, product, Lipitor, but Aromasin, Xalatan, in India. Jevtana, for advanced prostate Japanese regulators approved Nexium— Vfend, and Protonix as well. Still, the in- cancer, launched in Europe, and the Al- a decade after the drug’s US launch. dustry giant had five products that sold legra family of allergy products launched $2 billion or more, and revenues that in the US on an over-the-counter basis. Lost market exclusivity included Tax- 8. Johnson & Johnson, topped $500 million in 18 countries while struggling to put manufacturing outside the US. It also acquired King for otere, Xatral, and Nasacort in the US problems behind it, took a commanding $3.6 billion, providing a broader profile and Aprovel in Western Europe. position in the orthopedic market with in pain, and sold formulation specialist its $21.3 billion acquisition of medical- Capsugel. Approvals included Xalkori 5. Roche gained simultaneous equipment maker Synthes. It won ap- (crizotinib) for some lung cancers with FDA approval for Zelboraf, a targeted proval for Zytiga (for late-stage prostate the ALK gene. therapy for metastatic melanoma, and cancer) and the anticoagulant Xarelto. its companion diagnostic test—a first. J&J exited the drug-eluting stent market 2. Novartis won 15 approvals in It also acquired Anadys, a hepatitis it helped create. It sold off its Jannsen the United States, the EU, and Japan. C specialist, for $230 million, and dermatology business and the US rights Among them was US approval for Ar- announced a partnership with Evotec to St. Joseph’s aspirin, and bought the capta Inhalr for COPD. It also launched to develop oncology biomarkers. In a over-the-counter brands of India’s J.B. the oral MS drug Gilenya. While still controversial decision, FDA withdrew ap- Chemicals & Pharmaceuticals. integrating Alcon, the world’s largest proval of Roche’s Avastin for breast can- eyecare company, acquired last year, cer—though CMS announced it would continue to reimburse for it. For the first 9. Abbott announced plans to split Novartis bought Genoptix, a diagnostics itself into two companies: a medical company, for $458 million, and hit a key time, the family-owned bloc of Roche products company focused on medical landmark as Sandoz’s generic version shares dipped below 50 percent when devices, branded generics, and nutrition- of the anticoagulant enoxaparin became Maia Oeri dropped out of the group. als; and a research-based pharmaceuti- the company’s first “generic blockbust- cal company. The spinoff is slated to er,” with sales of more than $1 billion. 6. GlaxoSmithKline announced take place late this year. Abbott also the $660 million sale of 17 noncore received European approval for a new 3. Merck gained FDA and EU approv- OTC brands, including Beano, Goody’s, absorbable heart stent, and filed for al for Victrelis, the first new medicine for Ecotrin, Fiber Choice, Sominex, and multiple new indications for Humira. chronic hepatitis C in almost a decade. Tagamet, to Prestige Brands. US ap- Other approvals included Juvisync, provals included Benlysta, the first new lupus treatment in more than 50 10. Eli Lilly successfully fended a combination of the diabetes drug off a challenge to its Cymbalta patent Januvia with the statin Zocor. Merck years (developed with Human Genome in federal court, preserving its market also bought Inspire, an ophthalmic spe- Sciences); the anticonvulsant Potigal exclusivity until at least June 2013. It cialty firm, for $430 million and formed (developed with Valeant); and Horizant won US and EU market approval for By- alliances with India’s Sun Pharma (to for restless leg syndrome (developed dureon, the diabetes drug it developed promote branded generics in emerging with XenoPort). with Amylin, only to have the nine-year- markets) and Parexel (to pursue biosimi- old partnership break up in November. lars). As the year ended, CEO Kenneth Frazier was appointed chairman, replac- 7. AstraZeneca sold its Astra It announced a strategic alliance with Tech subsidiary, which makes dental im- Boehringer Ingelheim focused on dia- ing Richard Clark. plants and medical devices for surgery betes. The partnership won US and UK and urology, to Dentsply for $1.8 billion. approval for Tradjenta/Trajenta. In July, 4. Sanofi acquired Genzyme for $20 FDA approved Brilinta, AZ’s new antico- Lilly acquired the animal health busi- billion in April, the largest of 30 new agulant, reversing its 2010 rejection of ness of Janssen, a Johnson & Johnson transactions in 2011. Others included the drug, as well as giving the nod to company. About the Authors Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Life Sciences Patrick Clinton is Marketing Director in the Health & Life Sciences practice Practice. He can be reached at Jerry.Cacciotti@oliverwyman.com of Oliver Wyman. He can be reached at Patrick.Clinton@oliverwyman.com

×